Drug facts

Molecule

Zoledronic Acid

Generics already compete: 15 makers on the market. 24 A-rated products from 15 makers substitute at the counter.

Zometa was first approved by the FDA on 08/20/2001 under NDA 021223; the application holder is Novartis Pharmaceuticals Corp. The Orange Book lists NDA 021223 as discontinued.

The latest NADAC for ZOLEDRONIC ACID 5 MG/100 ML is $0.47 per mL (as of 10/28/2026).

Holder Novartis Pharmaceuticals CorpApplication NDA 021223Approved 08/20/2001

01Patents and exclusivity

When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.

462days until the latest Zometa patent expires

ExclusivityPatent onlyOpen to generics
Today
Approved08/20/2001
Last patent02/05/2028
20022006201020142018202220262030
Latest patent
02/05/2028Zometa
Orange Book
Later patents, other products
Reclast 08/05/2028
Orange Book

02Competition

Generics
15 generic makers
Orange Book
Staged generics
11 passed FDA review, awaiting market entry
FDA
First generic approved
03/04/2013
Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Zoledronic Acid profile.See what is included

03Supply and price

FDA drug shortage
ClearNot on the current shortage list
FDA shortages
NADAC
$0.47 per mLZOLEDRONIC ACID 5 MG/100 ML, as of 10/28/2026
CMS NADAC
Latest recall
05/23/2024Class II, Zoledronic Acid Injection 5mg/100ml Ster..., Dr. Reddy's Laboratories, Inc.
FDA enforcement

04Product

Application holder
Novartis Pharmaceuticals Corp
Orange Book
Application
NDA 021223
Orange Book
First approved
08/20/2001
Orange Book
Dosage forms
injectable
Routes
intravenous
Other brand names
Reclast
Status
NDA 021223 discontinued
Orange Book

Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.